51
|
Baptista A, Silva F, Porteiro J, Míguez J, Pinto G, Fernandes L. On the Physical Vapour Deposition (PVD): Evolution of Magnetron Sputtering Processes for Industrial Applications. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/j.promfg.2018.10.125] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
52
|
Stoupa A, Samara-Boustani D, Flechtner I, Pinto G, Jourdon I, González-Briceño L, Bidet M, Laborde K, Chevenne D, Millischer AE, Lottmann H, Blanc T, Aigrain Y, Polak M, Beltrand J. Efficacy and Safety of Continuous Subcutaneous Infusion of Recombinant Human Gonadotropins for Congenital Micropenis during Early Infancy
. Horm Res Paediatr 2017; 87:103-110. [PMID: 28081535 DOI: 10.1159/000454861] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 11/28/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Early postnatal administration of gonadotropins to infants with congenital hypogonadotropic hypogonadism (CHH) can mimic minipuberty, thereby increasing penile growth. We assessed the effects of gonadotropin infusion on stretched penile length (SPL) and hormone levels in infants with congenital micropenis. METHODS Single-center study including 6 males with micropenis in case of isolated CHH (n = 4), panhypopituitarism (n = 1), and partial androgen insensitivity syndrome (PAIS; n = 1). Patients were evaluated at baseline, monthly and at the end of the study through a clinical examination (SPL, testicular position and size), serum hormone assays (testosterone, luteinizing hormone, follicle-stimulating hormone, inhibin B, anti-Müllerian hormone [AMH]), and ultrasound of penis/testes. RESULTS In CHH, significant increases occurred in serum testosterone (from undetectable level to 3.5 ± 4.06 ng/mL [12.15 ± 14.09 nmol/L]), SPL (from 13.8 ± 4.5 to 42.6 ± 5 mm; p < 0.0001), inhibin B (from 94.8 ± 74.9 to 469.4 ± 282.5 pg/mL, p = 0.04), and AMH (from 49.6 ± 30.6 to 142 ± 76.5 ng/mL, p = 0.03). Micropenis was corrected in all patients, except one. On treatment, in the patient with PAIS, SPL was increased from 13 to 38 mm. CONCLUSIONS Early gonadotropin infusion is a safe, well-tolerated and effective treatment. The effect in PAIS has not been reported previously. Long-term follow-up is needed to assess the impact, if any, on future fertility and reproduction.
.
Collapse
|
53
|
Mauhin W, Habarou F, Gobin S, Servais A, Brassier A, Grisel C, Roda C, Pinto G, Moshous D, Ghalim F, Krug P, Deltour N, Pontoizeau C, Dubois S, Assoun M, Galmiche L, Bonnefont JP, Ottolenghi C, de Blic J, Arnoux JB, de Lonlay P. Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood. Orphanet J Rare Dis 2017; 12:3. [PMID: 28057010 PMCID: PMC5217205 DOI: 10.1186/s13023-016-0550-8] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Accepted: 12/07/2016] [Indexed: 12/11/2022] Open
Abstract
Background Lysinuric protein intolerance (LPI) is a rare metabolic disease resulting from recessive-inherited mutations in the SLC7A7 gene encoding the cationic amino-acids transporter subunit y+LAT1. The disease is characterised by protein-rich food intolerance with secondary urea cycle disorder, but symptoms are heterogeneous ranging from infiltrative lung disease, kidney failure to auto-immune complications. This retrospective study of all cases treated at Necker Hospital (Paris, France) since 1977 describes LPI in both children and adults in order to improve therapeutic management. Results Sixteen patients diagnosed with LPI (12 males, 4 females, from 9 families) were followed for a mean of 11.4 years (min-max: 0.4-37.0 years). Presenting signs were failure to thrive (n = 9), gastrointestinal disorders (n = 2), cytopenia (n = 6), hyperammonemia (n = 10) with acute encephalopathy (n = 4) or developmental disability (n = 3), and proteinuria (n = 1). During follow-up, 5 patients presented with acute hyperammonemia, and 8 presented with developmental disability. Kidney disease was observed in all patients: tubulopathy (11/11), proteinuria (4/16) and kidney failure (7/16), which was more common in older patients (mean age of onset 17.7 years, standard deviation 5.33 years), with heterogeneous patterns including a lupus nephritis. We noticed a case of myocardial infarction in a 34-year-old adult. Failure to thrive and signs of haemophagocytic-lymphohistiocytosis were almost constant. Recurrent acute pancreatitis occurred in 2 patients. Ten patients developed an early lung disease. Six died at the mean age of 4 years from pulmonary alveolar proteinosis. This pulmonary involvement was significantly associated with death. Age-adjusted plasma lysine concentrations at diagnosis showed a trend toward increased values in patients with a severe disease course and premature death (Wilcoxon p = 0.08; logrank, p = 0.17). Age at diagnosis was a borderline predictor of overall survival (logrank, p = 0.16). Conclusions As expected, early pulmonary involvement with alveolar proteinosis is frequent and severe, being associated with an increased risk of death. Kidney disease frequently occurs in older patients. Cardiovascular and pancreatic involvement has expanded the scope of complications. A borderline association between increased levels of plasma lysine and poorer outome is suggested. Greater efforts at prevention are warranted to optimise the long-term management in these patients.
Collapse
Affiliation(s)
- Wladimir Mauhin
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Florence Habarou
- Metabolic Biochemistry, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Stéphanie Gobin
- Molecular Genetics, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Aude Servais
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France.,Nephrology Unit, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Anaïs Brassier
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Coraline Grisel
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Célina Roda
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Graziella Pinto
- Endocrinoloy Unit, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Despina Moshous
- Paediatric Immunology, Haematology and Rheumatology, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Fahd Ghalim
- Gastroenterology, Kremlin Bicêtre Hospital, AP-HP, University Paris Sud, Paris, France
| | - Pauline Krug
- Nephrology, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Nelly Deltour
- Molecular Genetics, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Clément Pontoizeau
- Metabolic Biochemistry, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Sandrine Dubois
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Murielle Assoun
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Louise Galmiche
- Anatomopathology, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Jean-Paul Bonnefont
- Molecular Genetics, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Chris Ottolenghi
- Metabolic Biochemistry, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Jacques de Blic
- Pneumology, Hospital Necker Enfants Malades, AP-HP, University Paris Descartes, Paris, France
| | - Jean-Baptiste Arnoux
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Pascale de Lonlay
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France. .,Reference Center of Metabolic Disease Unit, Université Paris Descartes, Hôpital Necker-Enfants Malades, Institute Imagine, INSERM-U781, 149 rue de Sèvres, 75015, Paris, France.
| |
Collapse
|
54
|
Pellacani C, Cassoni F, Bocchi C, Martino A, Pinto G, Fontana F, Furlini M, Buschini A. Cyto- and genotoxic profile of groundwater used as drinking water supply before and after disinfection. J Water Health 2016; 14:901-913. [PMID: 27959869 DOI: 10.2166/wh.2016.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The assessment of the toxicological properties of raw groundwater may be useful to predict the type and quality of tap water. Contaminants in groundwater are known to be able to affect the disinfection process, resulting in the formation of substances that are cytotoxic and/or genotoxic. Though the European directive (98/83/EC, which establishes maximum levels for contaminants in raw water (RW)) provides threshold levels for acute exposure to toxic compounds, the law does not take into account chronic exposure at low doses of pollutants present in complex mixture. The purpose of this study was to evaluate the cyto- and genotoxic load in the groundwater of two water treatment plants in Northern Italy. Water samples induced cytotoxic effects, mainly observed when human cells were treated with RW. Moreover, results indicated that the disinfection process reduced cell toxicity, independent of the biocidal used. The induction of genotoxic effects was found, in particular, when the micronucleus assay was carried out on raw groundwater. These results suggest that it is important to include bio-toxicological assays as additional parameters in water quality monitoring programs, as their use would allow the evaluation of the potential risk of groundwater for humans.
Collapse
Affiliation(s)
- C Pellacani
- Department of Neuroscience, School of Medicine, University of Parma, Parma, Italy E-mail: ; Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy; Department of Life Sciences, University of Parma, Parma, Italy
| | - F Cassoni
- Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy
| | - C Bocchi
- Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy
| | - A Martino
- Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy
| | - G Pinto
- Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy
| | - F Fontana
- Arpae Emilia-Romagna, Sezione Provinciale di Parma, Parma, Italy
| | - M Furlini
- Department of Life Sciences, University of Parma, Parma, Italy
| | - A Buschini
- Department of Life Sciences, University of Parma, Parma, Italy
| |
Collapse
|
55
|
Felix O, Amaddeo A, Olmo Arroyo J, Zerah M, Puget S, Cormier-Daire V, Baujat G, Pinto G, Fernandez-Bolanos M, Fauroux B. Central sleep apnea in children: experience at a single center. Sleep Med 2016; 25:24-28. [PMID: 27823711 DOI: 10.1016/j.sleep.2016.07.016] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2016] [Revised: 07/12/2016] [Accepted: 07/14/2016] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Central sleep apnea (CSA) syndromes are rare in children and data in children over one year of age are scarce. The aim of the study was to describe the sleep characteristics, underlying disorders, management, and outcome of children with CSA. PATIENTS/METHODS A retrospective chart review of all children >1 year of age, diagnosed with CSA on a laboratory sleep study during a 20-month period, was performed. CSA was defined by a central apnea index (CAI) >5 events/h. The clinical management and the patient's outcome were analyzed. RESULTS Eighteen of 441 (4.1%) patients recorded during the study period had CSA. The median CAI, pulse oximetry, and oxygen desaturation index were 13/h (range 6-146), 96% (93-98%), and 18/h (6-98), respectively. Neurosurgical pathologies represented the most common underlying disorders with Arnold-Chiari malformation in four and ganglioglioma in three patients. Other underlying disorders were Prader-Willi syndrome (N = 3), achondroplasia (N = 2), and Down syndrome, with one patient having an achondroplasia and a Down syndrome. The remaining six patients had other genetic diseases. The most common investigation was brain magnetic resonance imaging (MRI). Individualized management with neurosurgery and/or chemotherapy, continuous positive airway pressure (in two patients having associated obstructive events), or noninvasive ventilation resulted in an improvement in CSA and the clinical presentation in 11 patients. CONCLUSION CSA is rare in children >1 year of age. Underlying disorders are dominated by neurosurgical disorders. Individualized management is able to improve CSA and the clinical condition in most patients.
Collapse
Affiliation(s)
- Orlane Felix
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Alessandro Amaddeo
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker Enfants-Malades, Paris, France; Paris Descartes University, Paris, France.
| | - Jorge Olmo Arroyo
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Michel Zerah
- Paris Descartes University, Paris, France; Pediatric Neurosurgery, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Stephanie Puget
- Paris Descartes University, Paris, France; Pediatric Neurosurgery, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Valerie Cormier-Daire
- Paris Descartes University, Paris, France; Genetic Department, Imagine Institute, Paris, France
| | | | - Graziella Pinto
- Pediatric Endocrinology, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Marta Fernandez-Bolanos
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker Enfants-Malades, Paris, France
| | - Brigitte Fauroux
- Pediatric Noninvasive Ventilation and Sleep Unit, AP-HP, Hôpital Necker Enfants-Malades, Paris, France; Paris Descartes University, Paris, France; Inserm U955, Team 13, Créteil Université, Paris XII, Créteil, France
| |
Collapse
|
56
|
Le Goff C, Rogers C, Le Goff W, Pinto G, Bonnet D, Chrabieh M, Alibeu O, Nistchke P, Munnich A, Picard C, Cormier-Daire V. Heterozygous Mutations in MAP3K7, Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome. Am J Hum Genet 2016; 99:407-13. [PMID: 27426734 DOI: 10.1016/j.ajhg.2016.06.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 06/01/2016] [Indexed: 11/17/2022] Open
Abstract
Cardiospondylocarpofacial (CSCF) syndrome is characterized by growth retardation, dysmorphic facial features, brachydactyly with carpal-tarsal fusion and extensive posterior cervical vertebral synostosis, cardiac septal defects with valve dysplasia, and deafness with inner ear malformations. Whole-exome sequencing identified heterozygous MAP3K7 mutations in six distinct CSCF-affected individuals from four families and ranging in age from 5 to 37 years. MAP3K7 encodes transforming growth factor β (TGF-β)-activated kinase 1 (TAK1), which is involved in the mitogen-activated protein kinase (MAPK)-p38 signaling pathway. MAPK-p38 signaling was markedly altered when expression of non-canonical TGF-β-driven target genes was impaired. These findings support the loss of transcriptional control of the TGF-β-MAPK-p38 pathway in fibroblasts obtained from affected individuals. Surprisingly, although TAK1 is located at the crossroad of inflammation, immunity, and cancer, this study reports MAP3K7 mutations in a developmental disorder affecting mainly cartilage, bone, and heart.
Collapse
Affiliation(s)
- Carine Le Goff
- Department of Medical Genetics, Reference Center for Skeletal Dysplasia, INSERM UMR 1163, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, Paris Descartes-Sorbonne Paris Cité University, AP-HP, Institut Imagine, and Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
| | - Curtis Rogers
- Greenwood Genetic Center Greenville Office, 14 Edgewood Drive, Greenville, SC 29605, USA
| | - Wilfried Le Goff
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, ICAN, Institute of Cardiometabolism and Nutrition (UMR_S1166), Integrative Biology of Atherosclerosis Team, 91 Boulevard de l'Hôpital, 75013 Paris, France
| | - Graziella Pinto
- Pediatric Endocrinology, Gynecology and Diabetes, Centre des Maladies Endocriniennes Rares de la Croissance, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
| | - Damien Bonnet
- Centre de Référence Malformations Cardiaques Congénitales Complexes-M3C, Hôpital Universitaire Necker-Enfants Malades, Université Paris Descartes, 75015 Paris, France
| | - Maya Chrabieh
- Necker Branch, Laboratory of Human Genetics of Infectious Diseases, UMR 1163, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, 75015 Paris, France
| | - Olivier Alibeu
- Genomic Platform, INSERM UMR 1163, Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, 75015 Paris, France
| | - Patrick Nistchke
- Bioinformatic Platform, INSERM UMR 1163, Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, 75015 Paris, France
| | - Arnold Munnich
- Department of Medical Genetics, Reference Center for Skeletal Dysplasia, INSERM UMR 1163, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, Paris Descartes-Sorbonne Paris Cité University, AP-HP, Institut Imagine, and Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
| | - Capucine Picard
- Necker Branch, Laboratory of Human Genetics of Infectious Diseases, UMR 1163, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, 75015 Paris, France; Pediatric Hematology-Immunology-Rheumatology Unit, AP-HP, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France; Study Center of Immunodeficiencies, Hôpital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France
| | - Valérie Cormier-Daire
- Department of Medical Genetics, Reference Center for Skeletal Dysplasia, INSERM UMR 1163, Laboratory of Molecular and Physiopathological Bases of Osteochondrodysplasia, Paris Descartes-Sorbonne Paris Cité University, AP-HP, Institut Imagine, and Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France.
| |
Collapse
|
57
|
Maia F, Vassallo J, Pinto G, Pavin E, Matos P, Zantut-Wittmann D. Expression of Mcl-1 and Ki-67 in Papillary Thyroid Carcinomas. Exp Clin Endocrinol Diabetes 2016; 124:209-14. [DOI: 10.1055/s-0035-1569363] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- F. Maia
- Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil
| | - J. Vassallo
- Department of Pathology, Medical Science School, University of Campinas, São Paulo, Brazil
| | - G. Pinto
- Laboratory of Specialized Pathology, CAISM, University of Campinas, São Paulo, Brazil
| | - E. Pavin
- Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil
| | - P. Matos
- Department of Pathology, Medical Science School, University of Campinas, São Paulo, Brazil
| | - D. Zantut-Wittmann
- Endocrinology Division, Department of Internal Medicine, University of Campinas, São Paulo, Brazil
| |
Collapse
|
58
|
Muianga A, Falk K, Oludele J, Pinto G, Ali S, Tivane A, Galano G, Gudo ES, Lagerqvist N. Serological and molecular investigation of dengue, chikungunya and rift valey fever in febrile and non-febrile patients from northern Mozambique during Dengue outbreak, 2014. Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.02.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
59
|
Muianga A, Pinto G, Ali S, Oludele J, Monteiro V, Tivane A, Falk K, Gudo E. Occurrence of dengue in 2013 and 2014 in northern Mozambique: Is dengue an endemic disease in Mozambique? Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.02.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
60
|
Gudo E, Fafetine J, Alho P, Muianga A, Ali S, Pinto G, Tivane A, Monteiro V, Neves L. Mozambique experience in implementing One Health Surveillance as an innovative tool to understand the risk of spillover of emerging and zoonotic infections between wildlife and humans. Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.02.990] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
61
|
Stoupa A, González-Briceño L, Pinto G, Samara-Boustani D, Thalassinos C, Flechtner I, Beltrand J, Bidet M, Simon A, Piketty M, Laborde K, Morel Y, Bellanné-Chantelot C, Touraine P, Polak M. Inadequate cortisol response to the tetracosactide (Synacthen®) test in non-classic congenital adrenal hyperplasia: an exception to the rule? Horm Res Paediatr 2016; 83:262-7. [PMID: 25677445 DOI: 10.1159/000369901] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Accepted: 11/14/2014] [Indexed: 11/19/2022] Open
Abstract
AIMS To describe cortisol response to tetracosactide and to review the literature on adrenal function in non-classic congenital adrenal hyperplasia (NCCAH) patients. METHODS We compared cortisol responses to tetracosactide (250 μg) between NCCAH patients and a comparison group (CG) of patients with premature pubarche and normal tetracosactide test. An adequate cortisol response was defined as a peak ≥18 μg/dl. RESULTS We included 35 NCCAH patients (26 girls, 9 boys), whose mean age at testing was 7.0 years (0.8-15.6), and 47 patients in the CG (39 girls, 8 boys), whose mean age was 7.2 years (0.5-9.9). Baseline cortisol was significantly higher in the NCCAH group than in the CG [12.9 (4.3-22.2) vs. 9.7 (4.2-16.2) μg/dl, respectively; p = 0.0006]. NCCAH patients had lower cortisol peak response compared to the CG [18.2 (6.3-40) vs. 24.9 (12-30.3) μg/dl, respectively; p < 0.0001]. Peak cortisol was <18 μg/dl in 21/35 (60%) NCCAH patients versus 1/47 (2.1%) in the CG. No NCCAH patients had acute adrenal insufficiency, but 2 reported severe fatigue that improved with hydrocortisone. CONCLUSIONS The cortisol response to tetracosactide was inadequate (<18 μg/dl) in 60% of patients with NCCAH. Hydrocortisone therapy may deserve consideration when major stress (surgery, trauma, childbirth) or objectively documented fatigue occurs in NCCAH patients with inadequate cortisol response.
Collapse
Affiliation(s)
- Athanasia Stoupa
- Service d'Endocrinologie, Gynécologie et Diabétologie Pédiatriques, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
62
|
Duarte GM, Toucchet F, Espinola JP, Barreto CR, Paiva Silva GR, Almeida NR, Soares F, Pinto G, Marshall P. Abstract P5-17-10: Claudin -4 expression in carcinoma in situ and its association with local recurrence, clinical and immunohistochemistry characteristics. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-17-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Claudins are tight junction molecules and have been associated to breast cancer prognosis. Claudin-low intrinsic subtype of invasive carcinoma was described recently and has been related to high grade carcinoma, low junction molecules expression and worse chemotherapy response. However, it is unknown whether Claudins expression could be associated to carcinoma in situ prognostic. The aim of this study was evaluated the Claudin – 4 expression in carcinoma in situ and its association with local recurrence, clinical and immunohistochemistry characteristics.
Methods: A tissue microarray (TMA) block was constructed, using region of interesting, with 137 pure carcinoma in situ paraffin blocks of patients treated in the Women 's Hospital Prof. Dr. José Aristodemo Pinotti – UNICAMP from 1999 to 2009. The TMA was submitted to immunohistochemistry analyze to: Claudin-4, beta-catenin, e-caderin, estrogen receptor (ER), progesterone receptor (PR), HER-2 and Ki-67. It was calculated Claudin-4 score based in percentage and intensity of expression and categorized in: Claudin-4 low and Claudin – 4 high. The clinical data, treatment data (surgery, radiotherapy and tamoxifen use), local recurrence data (date and type) and death of each patient were reviewed in the medical records. The statistical analyze used Kaplan-Meier curve and log-rank test to disease free survival; qui-square and Fisher test to compare others variables; significance level of 5 % was used.
Results: It was possible to evaluate Claudin-4 expression in 86 cases, 88.4% were Claudin-4 high and 11.6% Claudin-4 low. The follow up mean was 69 months and local recurrence rate was 10.5 %. There was no significant difference in local recurrence rate between Claudin-4 high and Claudin-4 low (10.0% x 10.5% , p=1.0).The disease free survival was similar between Claudin-4 low and Claudin-4 high (p=0.559). The Claudin- 4 high was significantly more frequent in beta-catenin positive patients (p=0.048). There was no association significantly between Claudin-4 expression and: age (p=0.66), histology type (p=0.75), surgery (p=0.102), radiotherapy (p=0.29), tamoxifen use (p=0.432), ER (p=0.33), PR (p=1.0), HER-2 (p=0.23) and e-caderin (p=0.21).
Conclusion: Despite the Claudins are related to invasive carcinoma prognosis, our outcome did not show difference in local recurrence and disease free survival between Claudin-4 low and high in carcinoma in situ. The beta-catenin and claudin-4 expressions were significantly associated.
Citation Format: Duarte GM, Toucchet F, Espinola JP, Barreto CR, Paiva Silva GR, Almeida NR, Soares F, Pinto G, Marshall P. Claudin -4 expression in carcinoma in situ and its association with local recurrence, clinical and immunohistochemistry characteristics. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-17-10.
Collapse
Affiliation(s)
- GM Duarte
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - F Toucchet
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - JP Espinola
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - CR Barreto
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - GR Paiva Silva
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - NR Almeida
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - F Soares
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - G Pinto
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| | - P Marshall
- State University of Campinas - UNICAMP, Campinas, SP, Brazil; AC Camargo Cancer Center, Sao Paulo, SP, Brazil
| |
Collapse
|
63
|
Hammi M, Aziate G, Pinto G, Maaroufi A. Corrigenda: Electrical and Thermoelecrtical Behavior of Binary Composites of Phosphate Glass Loaded with Zinc Fillers: Promising Materials for Photovoltaic’s. J CHIN CHEM SOC-TAIP 2016. [DOI: 10.1002/jccs.201680241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
64
|
Pascal M, Pinto G, Carvalho A, Giannini M, Maia H. Evaluation of an anatomic dual-laminate composite resin shade guide. Dent Mater 2016. [DOI: 10.1016/j.dental.2016.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
65
|
Hammi M, Aziate G, Pinto G, Maaroufi A. Electrical and Thermoelectrical Behavior of Binary Composites of Phosphate Glass Loaded with Zinc Fillers: Promising Materials for Photovoltaic’s. J CHIN CHEM SOC-TAIP 2015. [DOI: 10.1002/jccs.201400254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
66
|
González Briceño L, Grill J, Bourdeaut F, Doz F, Beltrand J, Benabbad I, Brugières L, Dufour C, Valteau-Couanet D, Guerrini-Rousseau L, Aerts I, Orbach D, Alapetite C, Samara-Boustani D, Pinto G, Simon A, Touraine P, Sainte-Rose C, Zerah M, Puget S, Elie C, Polak M. Water and electrolyte disorders at long-term post-treatment follow-up in paediatric patients with suprasellar tumours include unexpected persistent cerebral salt-wasting syndrome. Horm Res Paediatr 2015; 82:364-71. [PMID: 25377653 DOI: 10.1159/000368401] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Accepted: 09/16/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Patients with brain tumours have a high risk of water and electrolyte disorders (WED). Postsurgery diabetes insipidus (DI) may be transient or permanent, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt-wasting syndrome (CSWS) are usually transient. METHODS Retrospective study, including patients with suprasellar tumours, treated at Hôpital Necker, Institut Gustave-Roussy or Institut Curie, in Île-de-France, between 2007 and 2011. WED were noted if they persisted >1 month after surgery. RESULTS 159 patients were included, 54.1% girls, 43.9% boys. Tumour types were: glioma (43.4%), craniopharyngioma (43.4%), germinoma (11.3%), others (1.9%). Age at diagnosis was 7.1 ± 4.6 years. The median time from end of treatment was 1.9 (0-7.8) years. DI was the most frequent disorder after tumour treatment (50.3%) and was significantly associated with surgery (p < 0.001). Persistent CSWS was present in 3.6%, persistent SIADH in 1.3%. Two cases of hypernatraemia were due to adipsia. Thyrotropin deficiency after treatment was noted in 68.9% of patients tested, adrenocorticotropin deficiency in 66.2%. CONCLUSIONS Patients with suprasellar tumours have a high incidence of long-term WED, mainly DI. Assessment of thyrotroph and corticotroph function, and thirst sensation, is necessary to diagnose and manage these disorders correctly. CSWS may be persistent in few patients and requires special attention to prescribe the appropriate care.
Collapse
Affiliation(s)
- Laura González Briceño
- Service d'Endocrinologie, Gynécologie et Diabétologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Pinto G, Cormier-Daire V, Le Merrer M, Samara-Boustani D, Baujat G, Fresneau L, Viaud M, Souberbielle JC, Pineau JC, Polak M. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort. Horm Res Paediatr 2015; 82:355-63. [PMID: 25323764 DOI: 10.1159/000364807] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Accepted: 05/23/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Hypochondroplasia (HCH) is a skeletal dysplasia characterized by disproportionate short stature. The aims of the study are to evaluate efficacy and safety of recombinant human growth hormone (r-hGH) therapy in HCH children, when compared with a historical cohort of untreated HCH children. METHODS Nineteen HCH patients with an initial height standard deviation score (SDS) ≤-2 and a mean age of 9.3 ± 3.1 years were treated with a mean r-hGH dose of 0.053 mg/kg/day over 3 years. Growth charts were derived from the historical cohort (n = 40). RESULTS Height gain in the treated population was +0.62 ± 0.81 SDS greater than in the general population, and +1.39 ± 0.9 SDS greater than in the historical untreated HCH cohort (mean gain of 7.4 ± 6.6 cm gain). A negative correlation between height gain and age at treatment initiation was reported (p = 0.04). There was no significant difference in response between patients with fibroblast growth factor receptor 3 mutations and those without. No treatment-related serious adverse events were reported. CONCLUSIONS r-hGH treatment is well tolerated and effective in improving growth in HCH patients, particularly when started early. The treatment effect varies greatly and must be evaluated for each patient during treatment to determine the value of continued therapy.
Collapse
Affiliation(s)
- Graziella Pinto
- Pediatric Endocrinology, Gynecology and Diabetes, Centre des Maladies Endocriniennes Rares de la Croissance, Hôpital Universitaire Necker-Enfants Malades, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Espiard S, Savagner F, Flamant F, Vlaeminck-Guillem V, Guyot R, Munier M, d'Herbomez M, Bourguet W, Pinto G, Rose C, Rodien P, Wémeau JL. A Novel Mutation in THRA Gene Associated With an Atypical Phenotype of Resistance to Thyroid Hormone. J Clin Endocrinol Metab 2015; 100:2841-8. [PMID: 26037512 DOI: 10.1210/jc.2015-1120] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT RTHα is a recently discovered resistance to thyroid hormone (RTH) due to mutation of THRA, the gene encoding TRα1, the thyroid hormone receptor. It has been described in a few patients with growth retardation, short stature, and a low free T4/free T3 (FT4/FT3) ratio. OBJECTIVE A 27-year-old patient presenting with dwarfism and a low FT4/FT3 ratio was investigated. DESIGN Clinical, biochemical, and radiological data were collected. Whole exome sequencing was performed in the patient and her relatives. RESULTS The patient exhibited congenital macrocytic anemia and severe bone malformation with growth retardation, dwarfism, clavicular agenesis, and abnormalities of the fingers, toes, and elbow joints. In adulthood, she presented with active behavior, chronic motor diarrhea, and hypercalcemia. Treatment with T3 led to heart rate acceleration, worsening of diarrhea, and TSH suppression. Low resting energy expenditure normalized on T3. rT3, SHBG, and IGF-1 remained normal. A de novo monoallelic missense mutation in THRA was discovered, the N359Y amino acid substitution (c.1075A>T), which affected both the TRα1 and the non-receptor isoform TRα2. The mutant TRα1 had a decrease in transcriptional activity related to decreased T3 binding and a dominant-negative effect on the wild-type receptor. CONCLUSIONS This patient presents a new phenotype including more significant bone abnormalities, lower TSH, and higher FT3 levels, without certainty of all her symptoms with the TRα1(N359Y) mutation. This case suggests that patients with a low FT4/FT3 ratio should be screened for THRA mutations, even if clinical and biological features differ from previous reported cases of RTHα.
Collapse
Affiliation(s)
- Stéphanie Espiard
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Frédérique Savagner
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Frédéric Flamant
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Virginie Vlaeminck-Guillem
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Romain Guyot
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Mathilde Munier
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Michele d'Herbomez
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - William Bourguet
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Graziella Pinto
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Christian Rose
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Patrice Rodien
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| | - Jean-Louis Wémeau
- Centre Hospitalier Régional Universitaire de Lille (S.E., J.-L.W.), Hôpital Huriez, Service d'endocrinologie et métabolisme, 59000 Lille, France; Unité Mixte de Recherche (UMR) Institut national de la santé et de la recherche médicale (Inserm) 1048 (F.S.), Institut des Maladies Métaboliques et Cardiovasculaires 31000 Toulouse, France; Equipe d'accueil 3143 (F.S.), Laboratoire de neurobiologie et transgenèse, Université d'Angers, France; Université de Lyon (F.F., R.G.), Centre National de la Recherche Scientifique (CNRS), Institut National Recherche Agronomique, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon, Institut de Génomique Fonctionnelle de Lyon, 69008 Lyon France; Centre de recherche en Cancérologie de Lyon (V.V.-G.), UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, 69008 Lyon, France; Service de Biochimie Sud (V.V.-G.), Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France; Inserm (M.M., P.R.), CNRS, UMR Inserm 1083 CNRS 6214, Université d'Angers, 49100 Angers, France; Centre Hospitalier Régional Universitaire de Lille (M.H.), Centre de Biopathologie, Service de médecine nucléaire, 59000 Lille, France; UMR Inserm 1054 CNRS 5048 (W.B.), Centre de Biochimie Structurale, Universités Montpellier 1 & 2, 34000 Montpellier, France; Hôpital Necker Enfants Malades (G.P.), service d'endocrinologie pédiatrique, 75015 Paris, France; Hôpital St-Vincent de Paul (C.R.), Institut Catholique de Lille Service d'oncologie et d'hématologie, 59000 Lille, France; and Centre Hospitalier Universitaire d'Angers (P.R.), centre de référence des maladies rares de la réceptivité hormonale, 49100 Angers, France
| |
Collapse
|
69
|
Al Dhafiri M, Ferneiny MG, Bader meunier B, De peufeilhoux L, Meni C, Barnerias C, Pinto G, Lambot K, Breton S, Bodemer C. Les immunoglobulines intraveineuses dans le traitement de la dermatomyosite paucisymptomatique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
70
|
Teissier R, Flechtner I, Colmenares A, Lambot-Juhan K, Baujat G, Pauwels C, Samara-Boustani D, Beltrand J, Simon A, Thalassinos C, Crosnier H, Latrech H, Pinto G, Le Merrer M, Cormier-Daire V, Souberbielle JC, Polak M. Characterization and prevalence of severe primary IGF1 deficiency in a large cohort of French children with short stature. Eur J Endocrinol 2014; 170:847-54. [PMID: 24662318 DOI: 10.1530/eje-14-0071] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE The prevalence of severe primary IGF1 deficiency (IGFD) is unclear. IGFD must be identified promptly as treatment with recombinant human IGF1 (rhIGF1) is now available. Our objective was to characterize and assess the prevalence of severe primary IGFD in a large cohort of patients evaluated for short stature at a pediatric endocrinology unit in France. DESIGN Observational study in a prospective cohort. METHODS Consecutive patients referred to our unit between 2004 and 2009 for suspected slow statural growth were included. Patients were classified into eight etiological categories. IGFD was defined by height ≤-3 SDS, serum IGF1 levels <2.5th percentile, GH sufficiency, and absence of causes of secondary IGFD. RESULTS Out of 2546 patients included, 337 (13.5%) were born small for gestational age and 424 (16.9%) had idiopathic short stature. In these two categories, we identified 30 patients who met our criterion for IGFD (30/2546, 1.2%). In these 30 patients, we assessed the response to IGF1 generation test, time course of IGF1 levels, and efficiency of GH replacement therapy. The results indicated that only four of the 30 children were definite or possible candidates for rhIGF1 replacement therapy. CONCLUSION The prevalence of severe primary IGFD defined using the standard criterion for rhIGF1 treatment was 1.2%, and only 0.2% of patients were eligible for rhIGF1 therapy.
Collapse
Affiliation(s)
- R Teissier
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - I Flechtner
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - A Colmenares
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - K Lambot-Juhan
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - G Baujat
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Pauwels
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - D Samara-Boustani
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - J Beltrand
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - A Simon
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - C Thalassinos
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - H Crosnier
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - H Latrech
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - G Pinto
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - M Le Merrer
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - V Cormier-Daire
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, FrancePediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - J C Souberbielle
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - M Polak
- Pediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, FrancePediatric EndocrinologyDiabetology and Gynecology Unit, Centre des Maladies Endocriniennes Rares de la CroissancePediatric Radiology UnitDepartment of Medical GeneticsHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, 75743 Paris Cedex 15, FrancePediatric UnitCentre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceOujda University HospitalOujda, MoroccoINSERM U871Université Paris Descartes, Sorbonne Paris Cité, Paris, FranceHormonal Biochemistry UnitHôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FranceINSERM U845Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
71
|
Flechtner I, Lambot-Juhan K, Teissier R, Colmenares A, Baujat G, Beltrand J, Ajaltouni Z, Pauwels C, Pinto G, Samara-Boustani D, Simon A, Thalassinos C, Le Merrer M, Cormier-Daire V, Polak M. Unexpected high frequency of skeletal dysplasia in idiopathic short stature and small for gestational age patients. Eur J Endocrinol 2014; 170:677-84. [PMID: 24536087 DOI: 10.1530/eje-13-0864] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To assess the prevalence of skeletal dysplasias (SDs) in patients with idiopathic short stature (ISS) or small for gestational age (SGA) status. SETTING Rare Endocrine/Growth Diseases Center in Paris, France. DESIGN A prospective study on consecutive patients with ISS and SGA enrolled from 2004 to 2009. METHOD We used a standardized workup to classify patients into well-established diagnostic categories. Of 713 patients with ISS (n=417) or SGA status (n=296), 50.9% underwent a skeletal survey. We chose patients labeled normal or with a prepubertal slowdown of growth as a comparison group. RESULTS Diagnoses were ISS (16.9%), SGA (13.5%), normal growth (24.5%), transient growth rate slowing (17.3%), endocrine dysfunction (12%), genetic syndrome (8.9%), chronic disease (5.1%), and known SD (1.8%). SD was found in 20.9% of SGA and 21.8% ISS patients and in only 13.2% in our comparison group. SD prevalence was significantly higher in the ISS group than in the comparison group, especially (50%) for patients having at least one parent whose height was <-2 SDS. Dyschondrosteosis and hypochondroplasia were the most frequently identified SD, and genetic anomaly was found in 61.5 and 30% respectively. Subtle SD was found equally in the three groups and require long-term growth follow-up to evaluate the impact on final height. CONCLUSION SD may explain more than 20% of cases of growth retardation ascribed to ISS or SGA, and this proportion is higher when parental height is <-2 SDS. A skeletal survey should be obtained in patients with delayed growth in a context of ISS or SGA.
Collapse
MESH Headings
- Adolescent
- Bone Diseases, Developmental/epidemiology
- Bone Diseases, Developmental/genetics
- Bone Diseases, Developmental/physiopathology
- Bone and Bones/abnormalities
- Bone and Bones/physiopathology
- Child
- Child, Preschool
- Cohort Studies
- Dwarfism/epidemiology
- Dwarfism/genetics
- Dwarfism/physiopathology
- Family Health
- Female
- Fetal Growth Retardation/epidemiology
- Fetal Growth Retardation/genetics
- Fetal Growth Retardation/physiopathology
- France/epidemiology
- Genetic Variation
- Growth Disorders/epidemiology
- Growth Disorders/etiology
- Growth Disorders/genetics
- Growth Disorders/physiopathology
- Hospitals, Pediatric
- Hospitals, Teaching
- Humans
- Infant
- Infant, Small for Gestational Age
- Limb Deformities, Congenital/epidemiology
- Limb Deformities, Congenital/genetics
- Limb Deformities, Congenital/physiopathology
- Lordosis/epidemiology
- Lordosis/genetics
- Lordosis/physiopathology
- Male
- Osteochondrodysplasias/epidemiology
- Osteochondrodysplasias/genetics
- Osteochondrodysplasias/physiopathology
- Prevalence
- Prospective Studies
- Referral and Consultation
Collapse
Affiliation(s)
- I Flechtner
- Pediatric Endocrinology, Gynecology and Diabetology, AP-HP, Imagine Institute Affiliate, Centre de Référence des Maladies Endocriniennes Rares
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Lesko B, Gudo ES, Vene S, Candido S, De Deus N, Pinto F, Pinto G, Manhica I, Falk K. Sero-epidemiological findings of zoonotic infections in Maputo suburban residents. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
73
|
Gudo E, Vene S, Manhica I, Deus N, Mandlaze A, Muianga A, Pinto G, Falk K. First evidence of circulation of chikungunya virus in Mozambique. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.409] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
74
|
Pinto Soares P, Queirós Inácio D, Vendeira L, Pinto G. EP-1291: Bladder tumors - 8 years experience of one Radiotherapy Service. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31409-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
75
|
Uettwiller F, Perlbarg J, Pinto G, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Melki I, Wouters C, Prieur AM, Landais P, Polak M, Quartier P. Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis. J Rheumatol 2013; 41:128-35. [DOI: 10.3899/jrheum.130311] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Objective.Growth retardation is a frequent complication of severe juvenile idiopathic arthritis (JIA). Biologic treatments may improve growth velocity by controlling systemic inflammation and reducing corticosteroids. Our goals were to compare growth velocity before and after the onset of biologic therapy and to determine whether the JIA subtype, the use of steroids, the requirement of one or several biologic agents, or the disease activity influenced growth velocity.Methods.We retrospectively analyzed the growth of children with JIA who never received growth hormone treatment, who started biologic treatment before puberty, and who were followed for at least 6 months afterward.Results.We included 100 children (33 boys). Median patient age was 7.1 years (range: 1.6–15.7) at the onset of biologic treatment and 11.0 years (range: 2.3–19.5) at the latest followup. Forty-six patients had received corticosteroid and 34 had received more than 1 biologic agent. Patient median height expressed as SD score (SDS) was 0.31 (range: −2.47 to 5.46) at disease onset, −0.24 (−3.63 to 2.90) at biologic therapy onset (p < 0.0001), and −0.15 (−4.95 to 3.52) at the latest followup (p = 0.171 compared to biologic treatment onset). Patients who required several biologics and systemic patients had a significantly lower growth velocity after the onset of biologic treatment. At the latest followup, 18% of our study group had low growth velocities and 19% were below −2SD or shorter than genetically programmed.Conclusion.In a subset of patients, particularly systemic JIA patients and patients who required more than 1 biologic, biologic therapy may be insufficient to restore normal growth velocity.
Collapse
|
76
|
Courtillot C, Baudoin R, Du Souich T, Saatdjian L, Tejedor I, Pinto G, Léger J, Polak M, Golmard JL, Touraine P. Monocentric study of 112 consecutive patients with childhood onset GH deficiency around and after transition. Eur J Endocrinol 2013; 169:587-96. [PMID: 23939920 DOI: 10.1530/eje-13-0572] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVES Our aim was to analyze a large cohort of childhood onset GH deficiency (CO-GHD) adults from a unique adult center, in order to analyze their clinical management and to study the metabolic and bone status in relation to GHD and to the other pituitary deficits, and to evaluate these parameters during the long-term follow-up. DESIGN AND METHODS Observational retrospective cohort study on 112 consecutive CO-GHD adults transferred to our unit from 1st January 1994 to 1st March 2012. Evaluation of GHD in pediatrics and after transition was conducted following consensus guidelines. Data recorded from pediatric and adult files were GH doses, pituitary magnetic resonance imaging and function, and metabolic and bone status. RESULTS Most patients presented with severe CO-GHD (64%) associated with other pituitary deficits (66%). CO-GHD was acquired in 56%, congenital in 33%, and idiopathic in 11% cases. Most patients (83%) stopped GH before transfer, at 16.3 years (median), despite persistence of GHD. Median age at transfer was 19.4 years. After transfer, GHD persisted in 101 patients and four of the 11 resolutive GHD were non idiopathic. IGF1 level was <-2 SDS in 70% of treated patients at transfer and in 34% of them after 3 years of treatment. Follow-up showed improvement in lipid profile and bone mineral density in severely persistent GHD patients under GH therapy. In multivariate analysis, the associated pituitary deficits seemed stronger determinant factors of metabolic and bone status than GHD. CONCLUSIONS This study raises concern about discontinuation of GH replacement therapy in pediatrics in severely persistent GHD patients and about the often insufficient dose of GH in the treatment of adult patients.
Collapse
Affiliation(s)
- Carine Courtillot
- AP-HP, Hôpital Pitié-Salpêtrière, Endocrinologie et Médecine de la Reproduction, 47-83, Boulevard de l'Hôpital, Paris F-75013, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
77
|
Elowe-Gruau E, Beltrand J, Brauner R, Pinto G, Samara-Boustani D, Thalassinos C, Busiah K, Laborde K, Boddaert N, Zerah M, Alapetite C, Grill J, Touraine P, Sainte-Rose C, Polak M, Puget S. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98:2376-82. [PMID: 23633208 DOI: 10.1210/jc.2012-3928] [Citation(s) in RCA: 133] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
CONTEXT Craniopharyngioma is a brain tumor whose high local recurrence rate has for a long time led to a preference for extensive surgery. Limited surgery minimizing hypothalamic damage may decrease the severe obesity rate at the expense of the need for radiotherapy to complete the treatment. OBJECTIVE We compared weight gain and local recurrence rates after extensive resection surgery (ERS) and hypothalamus-sparing surgery (HSS). DESIGN Our observational study compared a historical cohort managed with ERS between 1985 and 2002 to a prospective cohort managed with HSS between 2002 and 2010. SETTING The patients were treated in a pediatric teaching hospital in Paris, France. PATIENTS Thirty-seven boys and 23 girls were managed with ERS (median age, 8 years); 38 boys and 27 girls were managed with HSS (median age, 9.3 years). MAIN OUTCOME MEASURES Data were collected before and 6 months to 7 years after surgery. Body mass index (BMI) Z-score was used to assess obesity and the number of surgical procedures to assess local recurrence rate. RESULTS Mean BMI Z-score before surgery was comparable in the 2 cohorts (0.756 after ERS vs 0.747 after HSS; P = .528). At any time after surgery, mean BMI Z-score was significantly lower after HSS (eg, 1.889 SD vs 2.915 SD, P = .004 at 1 year). At last follow-up, the HSS cohort had a significantly lower prevalence of severe obesity (28% vs 54%, P < .05) and higher prevalence of normal BMI (38% vs 17%, P < .01). Mean number of surgical procedures was not significantly different in the 2 cohorts. CONCLUSIONS Hypothalamus-sparing surgery decreases the occurrence of severe obesity without increasing the local recurrence rate.
Collapse
Affiliation(s)
- E Elowe-Gruau
- Pediatric Endocrinology Gynecology and Diabetology Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
78
|
Figueira A, Monteiro A, Marques M, Carvalho A, Inácio D, Soares P, Reis T, Batel V, Pinto G. Pelvic radiotherapy: Do we really need high energy beams? Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
79
|
Figueira A, Monteiro A, Carvalho A, Reis T, Batel V, Alves L, Fontes P, Meireles P, Pinto G. EP-1206: Step-and-Shoot IMRT segmentation method - impact on QA and dose distribution. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33512-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
80
|
Meireles P, Figueira A, Monteiro A, Osório L, Soares A, Pinheiro J, Fontes M, Varzim P, Pinto G. EP-1046: Comparison between different forms of assessment of in-air PTV in breast irradiation with forward IMRT. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33352-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
81
|
Coupaye M, Lorenzini F, Lloret-Linares C, Molinas C, Pinto G, Diene G, Mimoun E, Demeer G, Labrousse F, Jauregi J, Laurier V, Basdevant A, Polak M, Thuilleaux D, Tauber M, Poitou C. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab 2013; 98:E328-35. [PMID: 23284006 DOI: 10.1210/jc.2012-2881] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Children with Prader-Willi syndrome (PWS) who receive GH treatment have improved growth and body composition; however, data are lacking for adults when treatment is discontinued after completion of growth. OBJECTIVES Our aim was to compare body composition and metabolic status in adults with PWS according to GH treatment in childhood and adolescence. DESIGN 64 adults (mean age: 25.4 years) with a genetic diagnosis of PWS were evaluated: 20 received GH in childhood (T), which had been discontinued at the time of this study, and 44 did not receive GH (C). Mean duration of treatment in the T group was 4.4 ± 2.7 years, age at baseline was 11.8 ± 2.7 years, mean time between the end of treatment and the current evaluation was 7.0 ± 4.4 years. MAIN OUTCOMES MEASURES Dual-energy X-ray absorptiometry was used to assess body composition and fasting biological analyses evaluated metabolic status. RESULTS (MEAN ± SD): Body mass index and percentage of fat mass were significantly lower in the T group (32.4 ± 10.3 vs 41.2 ± 11.1 kg/m(2), P = 0.05 and 44.0 ± 9.6 vs 50.1 ± 7.2%, P = 0.02, respectively). Insulinemia and HOMA-IR in non-diabetic subjects were significantly lower in the T group (5.8 ± 5.9 vs 13.9 ± 11.6 μUI/ml, P = 0.03, and 1.6 ± 1.3 vs 2.7 ± 2.1, P = 0.04, respectively). Non-diabetic and diabetic subjects from the T group had a significantly lower HbA1c. Lipid profiles were similar between groups. CONCLUSIONS GH treatment in childhood and adolescence is associated with significantly decreased body mass index and improved body composition and metabolic status in adults with PWS at several years after discontinuing treatment.
Collapse
Affiliation(s)
- Muriel Coupaye
- Service de nutrition, Hôpital Pitié Salpêtrière (AP-HP), 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
82
|
Pinto G, Galati D, Bompiani GD, Corcione F, Califano G, Colucci S, Florio A, Marcialis A, Maggioni-Moratti E. Topical 5′-Methylthioadenosine in the Treatment of Symptomatic Chronic Venous Insufficiency, Haemorrhoids and Superficial Phlebitis. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/bf03258400] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
83
|
Uettwiller F, Pinto G, Polak M, Quartier P. Croissance des enfants traités par biothérapie pour une arthrite juvénile idiopathique. Arch Pediatr 2012. [DOI: 10.1016/j.arcped.2012.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
84
|
Mercieri M, De Blasi RA, Palmisani S, Forte S, Cardelli P, Romano R, Pinto G, Arcioni R. Changes in cerebrospinal fluid magnesium levels in patients undergoing spinal anaesthesia for hip arthroplasty: does intravenous infusion of magnesium sulphate make any difference? A prospective, randomized, controlled study. Br J Anaesth 2012; 109:208-15. [PMID: 22661752 DOI: 10.1093/bja/aes146] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Most investigators have attributed the reduced postoperative pain or anaesthetic drug requirements in patients receiving i.v. magnesium sulphate (MgSO(4)) infusion during spinal or general anaesthesia to central N-methyl-d-aspartate (NMDA) receptor magnesium (Mg) activity. In this study, we investigated how cerebrospinal fluid (CSF) Mg concentrations change after spinal anaesthesia, and whether peripherally infusing MgSO(4) influences central Mg levels. METHODS Forty-five patients undergoing continuous spinal anaesthesia for hip arthroplasty were randomly assigned to receive either i.v. MgSO(4) at a dose of 50 mg kg(-1) diluted in 100 ml 0.9% saline solution followed by 15 mg kg(-1) h(-1) for 6 h or saline at the same volume [mean (sd) 64 (10) ml]. The changes in CSF and serum total and ionized Mg concentrations were assessed at six time points before and after spinal anaesthesia. Secondary outcome variables included serum and CSF electrolytes and proteins. RESULTS Thirty-five patients completed the study. We found that spinal anaesthesia reduced total and ionized Mg concentrations in CSF by about 10%. Increasing serum Mg concentration over 80% of the baseline value left CSF Mg levels unchanged. CONCLUSIONS Spinal anaesthesia unexpectedly reduced CSF total and ionized Mg concentrations in patients undergoing hip arthroplasty, although the mechanism is unclear. The dose used for peripheral MgSO(4) infusion in this study had no influence on central Mg concentrations in neurologically healthy patients undergoing spinal anaesthesia. If CSF Mg concentration is a reliable marker of Mg brain bioavailability, peripherally infused MgSO(4) during spinal anaesthesia is unlikely to influence central NMDA receptor activity.
Collapse
Affiliation(s)
- M Mercieri
- Pain Unit, Department of Medical-Surgical, Techno-Biomedical Sciences and Translational Medicine, Sapienza University of Rome, Ospedale Sant’Andrea, via di Grottarossa, 1035Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
85
|
Kalfa N, Fukami M, Philibert P, Audran F, Pienkowski C, Weill J, Pinto G, Manouvrier S, Polak M, Ogata T, Sultan C. Screening of MAMLD1 mutations in 70 children with 46,XY DSD: identification and functional analysis of two new mutations. PLoS One 2012; 7:e32505. [PMID: 22479329 PMCID: PMC3316539 DOI: 10.1371/journal.pone.0032505] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2011] [Accepted: 01/31/2012] [Indexed: 11/23/2022] Open
Abstract
More than 50% of children with severe 46,XY disorders of sex development (DSD) do not have a definitive etiological diagnosis. Besides gonadal dysgenesis, defects in androgen biosynthesis, and abnormalities in androgen sensitivity, the Mastermind-like domain containing 1 (MAMLD1) gene, which was identified as critical for the development of male genitalia, may be implicated. The present study investigated whether MAMLD1 is implicated in cases of severe 46,XY DSD and whether routine sequencing of MAMLD1 should be performed in these patients. Seventy children with severe non-syndromic 46,XY DSD of unknown etiology were studied. One hundred and fifty healthy individuals were included as controls. Direct sequencing of the MAMLD1, AR, SRD5A2 and NR5A1 genes was performed. The transactivation function of the variant MAMLD1 proteins was quantified by the luciferase method. Two new mutations were identified: p.S143X (c.428C>A) in a patient with scrotal hypospadias with microphallus and p.P384L (c.1151C>T) in a patient with penile hypospadias with microphallus. The in vitro functional study confirmed no residual transactivating function of the p.S143X mutant and a significantly reduced transactivation function of the p.P384L protein (p = 0.0032). The p.P359S, p.N662S and p.H347Q variants are also reported with particularly high frequency of the p.359T- p.662G haplotype in the DSD patients. Severe undervirilization in XY newborns can reveal mutations of MAMLD1. MAMLD1 should be routinely sequenced in these patients with otherwise normal AR, SRD5A2 and NR5A1genes.
Collapse
MESH Headings
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/genetics
- Base Sequence
- Child
- DNA-Binding Proteins/chemistry
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Disorder of Sex Development, 46,XY/diagnosis
- Disorder of Sex Development, 46,XY/genetics
- Female
- Genetic Testing
- Haplotypes
- Humans
- Infant, Newborn
- Male
- Membrane Proteins/genetics
- Models, Molecular
- Mutant Proteins/chemistry
- Mutant Proteins/genetics
- Mutant Proteins/metabolism
- Mutation
- Nuclear Proteins/chemistry
- Nuclear Proteins/genetics
- Nuclear Proteins/metabolism
- Pedigree
- Polymorphism, Genetic
- Protein Conformation
- Protein Structure, Tertiary
- Receptors, Androgen/genetics
- Sequence Analysis, DNA
- Steroidogenic Factor 1/genetics
- Transcription Factors/chemistry
- Transcription Factors/genetics
- Transcription Factors/metabolism
- Transcriptional Activation
Collapse
Affiliation(s)
- Nicolas Kalfa
- Service d'Hormonologie, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
- Service de Chirurgie et Urologie Pédiatrique, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
| | - Maki Fukami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Pascal Philibert
- Service d'Hormonologie, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
| | - Francoise Audran
- Service d'Hormonologie, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
| | - Catherine Pienkowski
- Unité d'Endocrinologie Pédiatrique, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Jacques Weill
- Clinique de Pédiatrie, Hôpital Jeanne de Flandre, CHU de Lille, Lille, France
| | - Graziella Pinto
- Unité d'Endocrinologie Pédiatrique, Hôpital Necker Enfants Malades, APHP, Paris, France
| | - Sylvie Manouvrier
- Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHU de Lille, Lille, France
| | - Michel Polak
- Unité d'Endocrinologie Pédiatrique, Hôpital Necker Enfants Malades, APHP, Paris, France
| | - Totsumo Ogata
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - Charles Sultan
- Service d'Hormonologie, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
- Service de Chirurgie et Urologie Pédiatrique, Hôpital Lapeyronie, CHU de Montpellier et UM1, Montpellier, France
- Unité d'Endocrinologie et Gynécologie Pédiatriques, Service de Pédiatrie, Hôpital Arnaud de Villeneuve et UM1, CHU de Montpellier, Montpellier, France
- * E-mail:
| |
Collapse
|
86
|
Garrido Puchalt N, Garcia-Velasco JA, Rivera R, Remohi J, Pellicer A, Simoes T, Pinto S, Marques C, Correia S, Pinto G, Figueiredo S, Santillan I, Verdu V, Parra M, Bajo JM, Macedo J, Coca S, Freour T, Dessolle L, Lammers J, Lattes S, Mansour W, Mirallie S, Jean M, Barriere P, Polyzos NP, Blockeel C, Verpoest W, De Vos M, Stoop D, Vloeberghs V, Camus M, Devroey P, Tournaye H. SESSION 20: FEMALE INFERTILITY 2. Hum Reprod 2012. [DOI: 10.1093/humrep/27.s2.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
87
|
Tufano R, Puntillo F, Draisci G, Pasetto A, Pietropaoli P, Pinto G, Catarci S, Cardone A, Varrassi G. ITalian Observational Study of the management of mild-to-moderate Post-Operative Pain (ITOSPOP). Minerva Anestesiol 2012; 78:15-25. [PMID: 21720283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND The multicenter observational ITalian Observational Study on the management of mild-to-moderate PostOperative Pain (ITOSPOP) was carried out in 24 hospitals to describe current postoperative pain management in Italy and the intensity of pain experienced by patients during the first 48 hours after surgery. METHODS Adult patients, after surgery expected to result in mild-moderate postoperative pain, underwent six evaluations. The primary endpoint was the level of organization and standardization of postoperative pain management. Secondary objectives included the intensity of postoperative pain, and an assessment of incident pain, postoperative analgesic and concomitant treatment administration. RESULTS Only 16.7% hospitals had an acute pain service and 41.7% hospitals applied a standardized protocol for postoperative pain management. The majority (>60%) of the 1952 patients monitored underwent all six assessments, >70% of which were performed by a physician. The proportion of patients with moderate pain decreased during the study period, but almost 10% of patients still experienced moderate pain at study end. Mild pain was reported by 50% of the patients for the entire study duration. At the final assessment, 5% of patients still presented with incident pain frequently interfering with daily activities. Most patients were treated with analgesics, but 20% of patients did not receive any pain medications despite experiencing pain. CONCLUSION The level of organization and standardization of postoperative pain management in Italian hospitals remains low. Postoperative analgesic treatment remained suboptimal and almost two-thirds of patients continued to experience pain.
Collapse
Affiliation(s)
- R Tufano
- Department of Anesthesia and Intensive Care, Federico II University, Naples, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
88
|
Uettwiller F, Pinto G, Polak M, Quartier P. Impact of biologics on growth in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2011. [PMCID: PMC3194490 DOI: 10.1186/1546-0096-9-s1-p139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
89
|
De Blasi RA, Tonelli E, Arcioni R, Mercieri M, Cigognetti L, Romano R, Pinto G. In vivo effects on human skeletal muscle oxygen delivery and metabolism of cardiopulmonary bypass and perioperative hemodilution. Intensive Care Med 2011; 38:413-21. [DOI: 10.1007/s00134-011-2404-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2011] [Accepted: 10/14/2011] [Indexed: 11/28/2022]
|
90
|
Philibert P, Paris F, Audran F, Kalfa N, Polak M, Thibaud E, Pinto G, Houang M, Zenaty D, Leger J, Mas JC, Pienkowski C, Einaudi S, Damiani D, Ten S, Sinha S, Poulat F, Sultan C. Phenotypic variation of SF1 gene mutations. Adv Exp Med Biol 2011; 707:67-72. [PMID: 21691958 DOI: 10.1007/978-1-4419-8002-1_16] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Pascal Philibert
- Service d'Hormonologie, Hôpital Lapeyronie, CHU Montpellier, Montpellier, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
91
|
Linglart A, Menguy C, Couvineau A, Auzan C, Gunes Y, Cancel M, Motte E, Pinto G, Chanson P, Bougnères P, Clauser E, Silve C. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011; 364:2218-26. [PMID: 21651393 DOI: 10.1056/nejmoa1012717] [Citation(s) in RCA: 104] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The skeletal dysplasia characteristic of acrodysostosis resembles the Albright's hereditary osteodystrophy seen in patients with pseudohypoparathyroidism type 1a, but defects in the α-stimulatory subunit of the G-protein (GNAS), the cause of pseudohypoparathyroidism type 1a, are not present in patients with acrodysostosis. We report a germ-line mutation in the gene encoding PRKAR1A, the cyclic AMP (cAMP)-dependent regulatory subunit of protein kinase A, in three unrelated patients with acrodysostosis and resistance to multiple hormones. The mutated subunit impairs the protein kinase A response to stimulation by cAMP; this explains our patients' hormone resistance and the similarities of their skeletal abnormalities with those observed in patients with pseudohypoparathyroidism type 1a.
Collapse
Affiliation(s)
- Agnès Linglart
- INSERM Unité 986, Hôpital St. Vincent de Paul, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Fonte D, Meireles P, Costa A, Alves L, Pinto G. 1075 poster TESTICULAR SEMINOMA: A 12 YEARS EPIDEMIOLOGICAL REVIEW OF THE EXPERIENCE OF A SINGLE INSTITUTION. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71197-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
93
|
Fonte D, Meireles P, Costa A, Pinto G. 743 poster BREAST CANCER IN ELDERLY WOMEN-TOLERANCE TO RADIATION THERAPY. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70865-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
94
|
Colmenares A, Pinto G, Taupin P, Giuseppe A, Odent T, Trivin C, Laborde K, Souberbielle JC, Polak M. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome. Horm Res Paediatr 2011; 75:123-30. [PMID: 20847547 DOI: 10.1159/000319709] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Accepted: 07/26/2010] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Prader-Willi syndrome (PWS) is a complex genetic disorder whose many manifestations include obesity and short stature. Diabetes, osteoporosis, and scoliosis are common. We evaluated the effects of human growth hormone (hGH). METHODS A prospective cohort study of 36 children (1-15 years of age) with genetically confirmed PWS who were given hGH (mean dose 0.033 ± 0.006 mg/kg/day) for 36 months. At baseline and once yearly, we evaluated growth, insulin-like growth factor-1 (IGF-1), body composition, bone mineral density (BMD), glucose tolerance, serum lipids, and spinal radiographs. RESULTS Height gain over the 3-year period was 1.2 SD score. Lean body mass increased significantly during each treatment year. Total body fat decreased by 5.42 and 1.17% in the 1st and 2nd years, respectively. BMD remained unchanged during therapy. IGF-1 and homeostasis model assessment index of insulin resistance increased, and glucose intolerance was found in 22.7% of patients at baseline and 0% at 3 years. None of the patients had diabetes. Their lipid profile improved. Scoliosis was present in 27.8% of the patients at baseline and 47.2% at 3 years. CONCLUSION GH treatment in children with PWS has multiple beneficial effects on growth and body composition. Tolerance is good, with an improvement in glucose metabolism, although IGF-1 levels and insulin resistance parameters should be monitored closely. The high rate of scoliosis warrants monitoring by a pediatric orthopedic surgeon.
Collapse
Affiliation(s)
- A Colmenares
- Pediatric Endocrinology and Diabetes Unit, Centre de référence pour le syndrome de Prader-Willi, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
95
|
Vassilieva E, Pinto G, Acacio de Barros J, Suppes P. Learning Pattern Recognition Through Quasi-Synchronization of Phase Oscillators. ACTA ACUST UNITED AC 2011; 22:84-95. [DOI: 10.1109/tnn.2010.2086476] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
96
|
Olivieri G, Marzocchella A, Salatino P, Andreozzi R, Pinto G, Pollio A. Bio-oil Production by Stichococcus Strains in Laboratory Scale Photobioreactors. J Biotechnol 2010. [DOI: 10.1016/j.jbiotec.2010.08.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
97
|
El Homrany M, Maaroufi A, Benavente R, Pereña JM, Pinto G, Halim M. Improvement of mechanical performance of epoxy resins filled with cobalt and chromium powders. J Appl Polym Sci 2010. [DOI: 10.1002/app.32554] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
98
|
Lebrun M, Richard N, Abeguilé G, David A, Coëslier Dieux A, Journel H, Lacombe D, Pinto G, Odent S, Salles JP, Taieb A, Gandon-Laloum S, Kottler ML. Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J Clin Endocrinol Metab 2010; 95:3028-38. [PMID: 20427508 DOI: 10.1210/jc.2009-1451] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Heterozygous GNAS inactivating mutations are known to induce pseudohypoparathyroidism type 1a when maternally inherited and pseudopseudohypoparathyroidism when paternally inherited. Progressive osseous heteroplasia (POH) is a rare disease of ectopic bone formation, and studies in different families have shown that POH is also caused by paternally inherited GNAS mutations. OBJECTIVE Our purpose was to characterize parental origin of the mutated allele in de novo cases of POH and to draw phenotype/genotype correlations according to maternal or paternal transmission of a same GNAS mutation. DESIGN AND SETTING We conducted a retrospective study on patients addressed to our referral center for the rare diseases of calcium and phosphorus metabolism. PATIENTS AND METHODS We matched 10 cases of POH with cases of pseudohypoparathyroidism type 1a carrying the same GNAS mutations. MAIN OUTCOME MEASURES The parental origin of the mutated allele was studied using informative intragenic polymorphisms and subcloning of PCR products. RESULTS Paternal origin of GNAS mutations was clearly demonstrated in eight POH cases including one patient with mutation in exon 1. Genotype/phenotype analyses suggest that there is no direct correlation between the ossifying process and the position of the inactivating GNAS mutation. It is, however, more severe in patients in whom origin of the mutation is paternal. Severe intrauterine growth retardation was clearly evidenced in paternally inherited mutations. CONCLUSIONS Clinical heterogeneity makes genetic counseling a delicate matter, especially in which paternal inheritance is concerned because it can lead to either a mild expression of pseudopseudohypoparathyroidism or a severe expression of POH.
Collapse
Affiliation(s)
- M Lebrun
- Department of Genetics and Reproduction, University Hospital-Caen, 14033 Caen, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
99
|
Halb C, Pinto G, Baujat G, Linglart A, Duquesne A, Souchon P, Barbe C, Bader-Meunier B. CL172 - Ostéoporose Idiopathique Juvénile : présentation d’une série de 24 patients. Arch Pediatr 2010. [DOI: 10.1016/s0929-693x(10)70389-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
100
|
Casali KR, Bertagnolli M, Pinto G, Dias LD, Rigatto KV, Schaan B, Irigoyen MC, Santos R. Chronic Treatment with an orally active formulation of Angiotensin‐(1‐7) improves autonomic control in SHR. FASEB J 2010. [DOI: 10.1096/fasebj.24.1_supplement.lb532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - G Pinto
- Institute of Cardiology of Rio Grande do SulPorto AlegreBrazil
| | - L D Dias
- Institute of Cardiology of Rio Grande do SulPorto AlegreBrazil
| | | | - Beatriz Schaan
- Institute of Cardiology of Rio Grande do SulPorto AlegreBrazil
| | - Maria Claudia Irigoyen
- Institute of Cardiology of Rio Grande do SulPorto AlegreBrazil
- Heart Institute of University of São PauloSão PauloBrazil
| | - Robson Santos
- Institute of Cardiology of Rio Grande do SulPorto AlegreBrazil
- Federal University of Minas GeraisBelo HorizonteBrazil
| |
Collapse
|